Medtronic PulseSelect PFA approval (2023)
The FDA cleared the first pulsed field ablation catheter for atrial fibrillation, reshaping the cardiac ablation market. Medtronic's PulseSelect system delivered targeted electric fields to heart tissue without the heat or cold effects of older methods.
PFA quickly became a preferred option for paroxysmal AFib due to lower complication rates.
PFA adoption surged, prompting competitors like Abbott, Boston Scientific, and J&J to accelerate their own programs.
Set the stage for the current competitive battlefield. Abbott's dual-energy device is the next step beyond this single-energy breakthrough.
